Vision to transform outcomes of generic medicines through patch technology.
ChemioCare is a development-stage biotech focused on transforming the outcomes of generic medicines through patch technology.
The technology uniquely combines high flux and sustained release into a matrix transdermal delivery system (adhesive patch). Our initial focus is on cancer supportive care, developing three transdermal patches to improve the lives of those affected by cancer.
Transdermal patches will address limitations with existing formulations by:
Eliminating peak blood levels
Reducing overall patient exposure to the medicine
Bypassing first pass metabolism
Improving patient compliance with a simplified, long-acting dosing regimen
The company is reformulating generic medicines that are well characterized and have a long and robust medical history. As result, ChemioCare will be able to leverage the 505(b)2 regulatory path, enabling:
a shortened development timeline,
and significantly reduced financial investment
Cancer Supportive Care Focus.
The company is using a lean development approach in a focused therapeutic area to maximize value creation opportunities. There is an exciting opportunity to expand into additional therapeutic areas after accelerating the supportive care products to market.
Our internal team and scientific advisors have a deep understanding of the unmet need in cancer supportive care, the opportunities for our transdermal platform to address those unmet needs. The team has extensive clinical development experience.
At ChemioCare our goal is to have a positive impact on the lives of patients and families impacted by cancer by developing products that build on the current treatment paradigm safely and effectively.